BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 794 | Download: 1712
Publication Name World Journal of Hepatology
Manuscript ID 81433
Country United States
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Manuscript Source Invited Manuscript
All Author List Chun-Ye Zhang, Shuai Liu and Ming Yang
ORCID
Author(s) ORCID Number
Chun-Ye Zhang http://orcid.org/0000-0003-2567-029X
Shuai Liu http://orcid.org/0000-0001-9695-2492
Ming Yang http://orcid.org/0000-0002-4895-5864
Funding Agency and Grant Number
Corresponding Author Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, Room 2203, NexGen Precision Building, 1030 Hitt Street, Columbia, MO 65211, United States. yangmin@health.missouri.edu
Key Words Chronic liver disease; Alcoholic liver disease; Non-alcoholic fatty liver disease; Hepatocellular carcinoma; Natural products; Inflammation; Oxidative stress; Treatment; Clinical trials
Core Tip Chronic liver disease (CLD) is a continuous process that causes a reduction of liver function lasting more than six months. CLD can be subclassified into alcoholic liver disease, non-alcoholic fatty liver disease, chronic viral infection, and autoimmune hepatitis, which can lead to liver fibrosis, cirrhosis, and cancer. Liver inflammation and oxidative stress are commonly associated with the development and progression of CLD. Therefore, anti-inflammatory and antioxidant agents are promising drugs for CLD treatment. Clinical trials are undergoing to evaluate their efficacy and safety.
Publish Date 2023-02-24 13:35
Citation Zhang CY, Liu S, Yang M. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy. World J Hepatol 2023; 15(2): 180-200
URL https://www.wjgnet.com/1948-5182/full/v15/i2/180.htm
DOI https://dx.doi.org/10.4254/wjh.v15.i2.180
Full Article (PDF) WJH-15-180.pdf
Full Article (Word) WJH-15-180.docx